The role of miRNAs in cancer: From pathogenesis to therapeutic implications

Future Oncology

Volumn 10, Issue 6, 2014, Pages 1027-1048

  Seven, Mehmet ^a   Karatas, Omer Faruk ^a,b   Duz, Mehmet Bugrahan ^a   Ozen, Mustafa ^a,c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ERZURUM TECHNICAL UNIVERSITY   (Turkey)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

cancer; diagnostic and prognostic biomarkers; miRNAs; oncogenes; tumor suppressor

Indexed keywords

ANTAGOMIR; ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; FLUOROURACIL; MICRORNA; MICRORNA 100; MICRORNA 10B; MICRORNA 125B; MICRORNA 141; MICRORNA 145; MICRORNA 146A; MICRORNA 155; MICRORNA 16; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 20A; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 29B; MICRORNA 31; MICRORNA 34A; MICRORNA 375; SMALL INTERFERING RNA; TAMOXIFEN; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; DNA METHYLATION; EPIGENETICS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; ANIMAL; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ANIMALS; EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; ONCOGENES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903171135     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.259     Document Type: Review

References (266)

1. Sevli S, Uzumcu A, Solak M, Ittmann M, Ozen M. The function of microRNAs, small but potent molecules, in human prostate cancer. Prostate Cancer Prostatic Dis. 13(3), 208-217 (2010
2. Di Leva G, Croce CM. miRNA profiling of cancer. Curr. Opin. Genetics Dev. 23(1), 3-11 (2013
3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993
4. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev. Biol. 216(2), 671-680 (1999
5. Reinhart BJ, Slack FJ, Basson M et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403(6772), 901-906 (2000
6. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 294(5543), 853-858 (2001
7. Pasquinelli AE, Reinhart BJ, Slack F et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408(6808), 86-89 (2000
8. Nikitina EG, Urazova LN, Stegny VN. MicroRNAs and human cancer. Exp. Oncol. 34(1), 2-8 (2012
9. Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 18(3), 215-222 (2012
10. Mo YY. MicroRNA regulatory networks and human disease. Cell Mol. Life Sci. 69(21), 3529-3531 (2012
11. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the microprocessor complex. Nature 432(7014), 231-235 (2004
12. Gregory RI, Yan KP, Amuthan G et al. The microprocessor complex mediates the genesis of microRNAs. Nature 432(7014), 235-240 (2004
13. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 4(3), 143-159 (2012
14. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 65(9), 3509-3512 (2005
15. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature 448(7149), 83-86 (2007
16. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC. Mammalian mirtron genes. Mol. Cell 28(2), 328-336 (2007
17. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10(2), 185-191 (2004
18. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 303(5654), 95-98 (2004
19. Lee Y, Ahn C, Han J et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956), 415-419 (2003
20. Merritt WM, Lin YG, Han LY et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359(25), 2641-2650 (2008
21. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409(6818), 363-366 (2001
22. Bhayani MK, Calin GA, Lai SY. Functional relevance of miRNA sequences in human disease. Mutat. Res. 731(1-2), 14-19 (2012
23. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293(5531), 834-838 (2001
24. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15(20), 2654-2659 (2001
25. Lee YS, Kim HK, Chung S, Kim KS, Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J. Biol. Chem. 280(17), 16635-16641 (2005
26. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: MicroRNAs can up-regulate translation. Science 318(5858), 1931-1934 (2007
27. Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 465(7298), 584-589 (2010
28. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 455(7209), 58-63 (2008
29. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc. Natl Acad. Sci. USA 103(11), 4034-4039 (2006
30. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 32(Database issue), D109-D111 (2004
31. Griffiths-Jones S, Grocock RJ, Van Dongen S, Bateman A, Enright AJ. miRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34(Database issue), D140-D144 (2006
32. Griffiths-Jones S, Saini HK, Van Dongen S, Enright AJ. miRBase: Tools for microRNA genomics. Nucleic Acids Res. 36(Database issue), D154-158 (2008
33. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 136(2), 215-233 (2009
34. Jansson MD, Lund AH. MicroRNA and cancer. Mol. Oncol. 6(6), 590-610 (2012
35. Mallory AC, Vaucheret H. Functions of microRNAs and related small RNAs in plants. Nat. Genet. 38(Suppl.), S31-S36 (2006
36. Majid S, Dar AA, Saini S et al. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 116(24), 5637-5649 (2010
37. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-Transcriptional regulation by microRNAs: Are the answers in sight?. Nat. Rev. Genet. 9(2), 102-114 (2008
38. Zou C, Xu Q, Mao F et al. miR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 11(11), 2137-2145 (2012
39. Schepeler T, Reinert JT, Ostenfeld MS et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 68(15), 6416-6424 (2008
40. Xiao B, Guo J, Miao Y et al. Detection of miR-106a in gastric carcinoma and its clinical significance. Clin. Chim. Acta. 400(1-2), 97-102 (2009
41. Xu Q, Liu LZ, Qian X et al. miR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res. 40(2), 761-774 (2012
42. Penson RT, Oliva E, Skates SJ et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. Gynecol. Oncol. 93(1), 98-106 (2004
43. Havelange V, Stauffer N, Heaphy CC et al. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer 117(20), 4696-4706 (2011
44. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and-145 in B-cell malignancies. Cancer Sci. 98(12), 1914-1920 (2007
45. Vogt M, Munding J, Gruner M et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 458(3), 313-322 (2011
46. Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res. 72(21), 5576-5587 (2012
47. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26(34), 5017-5022 (2007
48. He L, He X, Lim LP et al. A microRNA component of the p53 tumour suppressor network. Nature 447(7148), 1130-1134 (2007
49. Qian P, Zuo Z, Wu Z et al. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res. 71(20), 6463-6474 (2011
50. Tu HF, Lin SC, Chang KW. MicroRNA aberrances in head and neck cancer: Pathogenetic and clinical significance. Curr. Opin. Otolaryngol. Head Neck Surg. 21(2), 104-111 (2013
51. Navarro A, Marrades RM, Vinolas N et al. MicroRNAs expressed during lung cancer development are expressed in human pseudoglandular lung embryogenesis. Oncology 76(3), 162-169 (2009
52. Casanova-Salas I, Rubio-Briones J, Fernandez-Serra A, Lopez-Guerrero JA. miRNAs as biomarkers in prostate cancer. Clin. Transl. Oncol. 14(11), 803-811 (2012
53. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. miR-125 in normal and malignant hematopoiesis. Leukemia 26(9), 2011-2018 (2012
54. Enomoto Y, Kitaura J, Hatakeyama K et al. Emu/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 25(12), 1849-1856 (2011
55. Feng B, Wang R, Chen LB. Review of miR-200b and cancer chemosensitivity. Biomed. Pharmacother. 66(6), 397-402 (2012
56. Lambertini E, Lolli A, Vezzali F, Penolazzi L, Gambari R, Piva R. Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells. BMC Cancer 12, 445 (2012
57. Quintavalle C, Garofalo M, Zanca C et al. miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 31(7), 858-868 (2012
58. Pineau P, Volinia S, Mcjunkin K et al. miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl Acad. Sci. USA 107(1), 264-269 (2010
59. Gramantieri L, Fornari F, Ferracin M et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin. Cancer Res. 15(16), 5073-5081 (2009
60. Wang Z, Zhang H, He L et al. Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma. Onco Targets Ther. 6, 281-287 (2013
61. Mardente S, Mari E, Consorti F et al. HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncol. Rep. 28(6), 2285-2289 (2012
62. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27(12), 1788-1793 (2008
63. Asangani IA, Rasheed SA, Nikolova DA et al. MicroRNA-21 (miR-21) post-Transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27(15), 2128-2136 (2008
64. Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY, Yan M. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol. Rep. 27(4), 1019-1026 (2012
65. Dong CG, Wu WK, Feng SY, Wang XJ, Shao JF, Qiao J. Co-inhibition of microRNA-10b and microRNA-21 exerts synergistic inhibition on the proliferation and invasion of human glioma cells. Int. J. Oncol. 41(3), 1005-1012 (2012
66. Lakomy R, Sana J, Hankeova S et al. miR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci. 102(12), 2186-2190 (2011
67. Lan H, Lin CY, Yuan HY, Xiong B. [Overexpression of miR-21 promotes proliferation and reduces apoptosis in non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi 33(10), 742-746 (2011
68. Steele CW, Oien KA, Mckay CJ, Jamieson NB. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas 40(8), 1165-1171 (2011
69. Lu Z, Liu M, Stribinskis V et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31), 4373-4379 (2008
70. Zhang Z, Liu S, Shi R, Zhao G. miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-To-mesenchymal transition. Cancer Genet. 204(9), 486-491 (2011
71. Wu XJ, Li Y, Liu D, Zhao LD, Bai B, Xue MH. miR-27a as an Oncogenic microRNA of hepatitis B virus-related hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 14(2), 885-889 (2013
72. Li Z, Hu S, Wang J et al. miR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol. Oncol. 119(1), 125-130 (2010
73. Donnem T, Fenton CG, Lonvik K et al. MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS ONE 7(1), e29671 (2012
74. Baffa R, Fassan M, Volinia S et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol. 219(2), 214-221 (2009
75. Bloomston M, Frankel WL, Petrocca F et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297(17), 1901-1908 (2007
76. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol. 111(3), 478-486 (2008
77. Ueda T, Volinia S, Okumura H et al. Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11(2), 136-146 (2010
78. O'connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-Term hematopoietic output. Proc. Natl Acad. Sci. USA 107(32), 14235-14240 (2010
79. Ooi AG, Sahoo D, Adorno M, Wang Y, Weissman IL, Park CY. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc. Natl Acad. Sci. USA 107(50), 21505-21510 (2010
80. Sonoki T, Iwanaga E, Mitsuya H, Asou N. Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia. Leukemia 19(11), 2009-2010 (2005
81. Shi XB, Xue L, Yang J et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc. Natl Acad. Sci. USA 104(50), 19983-19988 (2007
82. Mattie MD, Benz CC, Bowers J et al. Optimized high-Throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 5, 24 (2006
83. O'day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 12(2), 201 (2010
84. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282(2), 1479-1486 (2007
85. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: Their role in tumor progression and response to therapy. Curr. Mol. Med. 12(1), 27-33 (2012
86. Le Sage C, Nagel R, Egan DA et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26(15), 3699-3708 (2007
87. Visone R, Russo L, Pallante P et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr. Relat. Cancer. 14(3), 791-798 (2007
88. Miller TE, Ghoshal K, Ramaswamy B et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 283(44), 29897-29903 (2008
89. Fu X, Wang Q, Chen J et al. Clinical significance of miR-221 and its inverse correlation with p27Kip(1) in hepatocellular carcinoma. Mol. Biol. Rep. 38(5), 3029-3035 (2011
90. Garofalo M, Quintavalle C, Di Leva G et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27(27), 3845-3855 (2008
91. Galardi S, Mercatelli N, Farace MG, Ciafre SA. NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res. 39(9), 3892-3902 (2011
92. Galardi S, Mercatelli N, Giorda E et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 282(32), 23716-23724 (2007
93. Chen Y, Zaman MS, Deng G et al. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev. Res. (Phila.) 4(1), 76-86 (2011
94. Chen WX, Hu Q, Qiu MT et al. miR-221/222: Promising biomarkers for breast cancer. Tumor Biol. 34(3), 1361-1370 (2013
95. Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14(11), 2348-2360 (2008
96. Wang K, Li PF. Foxo3a regulates apoptosis by negatively targeting miR-21. J. Biol. Chem. 285(22), 16958-16966 (2010
97. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65(14), 6029-6033 (2005
98. Zhang Z, Li Z, Gao C et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab. Invest. 88(12), 1358-1366 (2008
99. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2), 647-658 (2007
100. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-Time RT-PCR. Clin. Chem. 54(10), 1696-1704 (2008
101. Chan SH, Wu CW, Li AF, Chi CW, Lin WC. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res. 28(2A), 907-911 (2008
102. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 12(12), 2171-2176 (2008
103. Wang Q, Li YC, Wang J et al. miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc. Natl Acad. Sci. USA 105(8), 2889-2894 (2008
104. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18(3), 350-359 (2008
105. Viswanathan SR, Powers JT, Einhorn W et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 41(7), 843-848 (2009
106. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 1, e105 (2010
107. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38(7), e190-199 (2009
108. Liu X, Sempere LF, Galimberti F et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin. Cancer Res. 15(4), 1177-1183 (2009
109. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 67(22), 11001-11011 (2007
110. Wang X, Tang S, Le SY et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 3(7), e2557 (2008
111. Liu T, Tang H, Lang Y, Liu M, Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett. 273(2), 233-242 (2009
112. Huang S, He X, Ding J et al. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int. J. Cancer 123(4), 972-978 (2008
113. Nam EJ, Yoon H, Kim SW et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 14(9), 2690-2695 (2008
114. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 67(13), 6130-6135 (2007
115. Lerner M, Lundgren J, Akhoondi S et al. miRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle 10(13), 2172-2183 (2011
116. Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL. Androgen-regulated processing of the oncomir miR-27a, which targets prohibitin in prostate cancer. Hum. Mol. Genet. 21(14), 3112-3127 (2012
117. Kamazawa S, Kigawa J, Kanamori Y et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol. Oncol. 86(2), 171-176 (2002
118. Han BW, Feng DD, Li ZG et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum. Mol. Genet. 20(24), 4903-4915 (2011
119. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103(7), 2257-2261 (2006
120. Boominathan L. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev. 29(4), 613-639 (2010
121. Chen X, Gong J, Zeng H et al. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res. 70(7), 2728-2738 (2010
122. Wang Y, Lee CG. MicroRNA and cancer-focus on apoptosis. J. Cell. Mol. Med. 13(1), 12-23 (2009
123. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 70(1), 378-387 (2010
124. Wang L, Tang H, Thayanithy V et al. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res. 69(24), 9490-9497 (2009
125. Wong MY, Yu Y, Walsh WR, Yang JL. microRNA-34 family and treatment of cancers with mutant or wild-Type p53 (review). Int. J. Oncol. 38(5), 1189-1195 (2011
126. Dahiya R, Mccarville J, Lee C et al. Deletion of chromosome 11p15, p12, q22, q23-24 loci in human prostate cancer. Int. J. Cancer 72(2), 283-288 (1997
127. Ellsworth RE, Vertrees A, Love B, Hooke JA, Ellsworth DL, Shriver CD. Chromosomal alterations associated with the transition from in situ to invasive breast cancer. Ann. Surg. Oncol. 15(9), 2519-2525 (2008
128. Rasio D, Negrini M, Manenti G, Dragani TA, Croce CM. Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: Identification of three independent regions. Cancer Res. 55(18), 3988-3991 (1995
129. Cole KA, Attiyeh EF, Mosse YP et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol. Cancer Res. 6(5), 735-742 (2008
130. Hagman Z, Larne O, Edsjo A et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int. J. Cancer 127(12), 2768-2776 (2010
131. Liang Y. An expression meta-Analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med. Genomics 1, 61 (2008
132. Toyota M, Suzuki H, Sasaki Y et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 68(11), 4123-4132 (2008
133. Li Y, Guessous F, Zhang Y et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69(19), 7569-7576 (2009
134. Guessous F, Zhang Y, Kofman A et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9(6), 1031-1036 (2010
135. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101(9), 2999-3004 (2004
136. Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64(11), 3753-3756 (2004
137. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21(9), 1025-1030 (2007
138. Nadiminty N, Tummala R, Lou W et al. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS ONE 7(3), e32832 (2012
139. Yu F, Yao H, Zhu P et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6), 1109-1123 (2007
140. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120(5), 635-647 (2005
141. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39(5), 673-677 (2007
142. Landi MT, Zhao Y, Rotunno M et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 16(2), 430-441 (2010
143. Helland A, Anglesio MS, George J et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS ONE 6(4), e18064 (2011
144. Childs G, Fazzari M, Kung G et al. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol. 174(3), 736-745 (2009
145. Chang TC, Zeitels LR, Hwang HW et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc. Natl Acad. Sci. USA 106(9), 3384-3389 (2009
146. Boyerinas B, Park SM, Shomron N et al. Identification of let-7-regulated oncofetal genes. Cancer Res. 68(8), 2587-2591 (2008
147. Johnson CD, Esquela-Kerscher A, Stefani G et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 67(16), 7713-7722 (2007
148. Wu H, Zhu S, Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 19(4), 439-448 (2009
149. Hanna JA, Hahn L, Agarwal S, Rimm DL. In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. Lab. Invest. 92(10), 1390-1397 (2012
150. Bracken CP, Gregory PA, Kolesnikoff N et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68(19), 7846-7854 (2008
151. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22(7), 894-907 (2008
152. Zhang H, Su SB, Zhou QM, Lu YY. [Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells]. Ai Zheng 28(5), 493-499 (2009
153. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67(18), 8699-8707 (2007
154. Adam L, Zhong M, Choi W et al. miR-200 expression regulates epithelial-To-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 15(16), 5060-5072 (2009
155. Duns G, Van Den Berg A, Van Dijk MC et al. The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared with the proximal tubular epithelial cells of the kidney. Genes Chromosomes Cancer 52(2), 165-173 (2013
156. Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 15(2), 180-191 (2013
157. Elson-Schwab I, Lorentzen A, Marshall CJ. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS ONE 5(10), (2010
158. Gregory PA, Bert AG, Paterson EL et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10(5), 593-601 (2008
159. Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol. Therapy 10(3), 219-222 (2010
160. Creighton CJ, Gibbons DL, Kurie JM. The role of epithelial-mesenchymal transition programming in invasion and metastasis: A clinical perspective. Cancer Manag. Res. 5, 187-195 (2013
161. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: The implications for cancer research. Nat. Rev. Cancer 10(6), 389-402 (2010
162. Raveche ES, Salerno E, Scaglione BJ et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109(12), 5079-5086 (2007
163. Calin GA, Ferracin M, Cimmino A et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353(17), 1793-1801 (2005
164. Wu M, Jolicoeur N, Li Z et al. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 29(9), 1710-1716 (2008
165. Ye Y, Wang KK, Gu J et al. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev. Res. (Phila.) 1(6), 460-469 (2008
166. Hu Z, Liang J, Wang Z et al. Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Human Mutat. 30(1), 79-84 (2009
167. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 68(7), 2530-2537 (2008
168. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, De La Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA 105(20), 7269-7274 (2008
169. Zheng J, Deng J, Xiao M et al. A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma. Cancer Res. 73(16), 5151-5162 (2013
170. Chin LJ, Ratner E, Leng S et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 68(20), 8535-8540 (2008
171. Paone A, Galli R, Fabbri M. MicroRNAs as new characters in the plot between epigenetics and prostate cancer. Front. Genet. 2, 62 (2011
172. Suh SO, Chen Y, Zaman MS et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis 32(5), 772-778 (2011
173. Fabbri M, Garzon R, Cimmino A et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl Acad. Sci. USA 104(40), 15805-15810 (2007
174. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435(7043), 834-838 (2005
175. Cao P, Deng Z, Wan M et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol. Cancer 9, 108 (2010
176. Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908), 1695-1699 (2008
177. Noonan EJ, Place RF, Pookot D et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28(14), 1714-1724 (2009
178. Leal JA, Lleonart ME. MicroRNAs and cancer stem cells: Therapeutic approaches and future perspectives. Cancer Lett. 338(1), 174-183 (2013
179. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821-5828 (2003
180. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007
181. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003
182. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int. J. Biochem. Cell Biol. 44(12), 2144-2151 (2012
183. Martinez NJ, Gregory RI. MicroRNA gene regulatory pathways in the establishment and maintenance of ESC identity. Cell Stem Cell 7(1), 31-35 (2010
184. Liu C, Kelnar K, Liu B et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 17(2), 211-215 (2011
185. Qian S, Ding JY, Xie R et al. MicroRNA expression profile of bronchioalveolar stem cells from mouse lung. Biochem. Biophys. Res. Commun. 377(2), 668-673 (2008
186. Wang L, Zhang D, Zhang C et al. A microRNA expression signature characterizing the properties of tumor-initiating cells for breast cancer. Oncol. Lett. 3(1), 119-124 (2012
187. Hao J, Zhao S, Zhang Y et al. Emerging role of microRNAs in cancer and cancer stem cells. J. Cell. Biochem. 115(4), 605-610 (2014
188. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163), 682-688 (2007
189. Spahn M, Kneitz S, Scholz CJ et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer 127(2), 394-403 (2010
190. Saini S, Majid S, Shahryari V et al. miRNA-708 control of CD44(+) prostate cancer-initiating cells. Cancer Res. 72(14), 3618-3630 (2012
191. Huang Q, Gumireddy K, Schrier M et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 10(2), 202-210 (2008
192. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7(20), 3112-3118 (2008
193. Leite KR, Sousa-Canavez JM, Reis ST et al. Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol. Oncol. 29(3), 265-269 (2011
194. Li N, Fu H, Tie Y et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275(1), 44-53 (2009
195. Tavazoie SF, Alarcon C, Oskarsson T et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175), 147-152 (2008
196. Watahiki A, Wang Y, Morris J et al. MicroRNAs associated with metastatic prostate cancer. PLoS ONE 6(9), e24950 (2011
197. Ishihara K, Sasaki D, Tsuruda K et al. Impact of miR-155 and miR-126 as novel biomarkers on the assessment of disease progression and prognosis in adult T-cell leukemia. Cancer Epidemiol. 36(6), 560-565 (2012
198. Marcucci G, Maharry KS, Metzeler KH et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: MiR-155 upregulation independently identifies high-risk patients. J. Clin. Oncol. 31(17), 2086-2093 (2013
199. Lee JA, Lee HY, Lee ES, Kim I, Bae JW. Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast. J. Breast Cancer 14(4), 269-275 (2011
200. Svoboda M, Sana J, Redova M et al. miR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn. Pathol. 7, 31 (2012
201. Iorio MV, Casalini P, Tagliabue E, Menard S, Croce CM. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur. J. Cancer 44(18), 2753-2759 (2008
202. Brase JC, Johannes M, Schlomm T et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 128(3), 608-616 (2011
203. Chen Q, Si Q, Xiao S et al. Prognostic significance of serum miR-17-5p in lung cancer. Med. Oncol. 30(1), 353 (2013
204. Yang M, Shen H, Qiu C et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur. J. Cancer 49(3), 604-615 (2013
205. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006
206. Yu SL, Chen HY, Chang GC et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13(1), 48-57 (2008
207. Ma Y, Yu S, Zhao W, Lu Z, Chen J. miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett. 298(2), 150-158 (2010
208. Min J, Zaslavsky A, Fedele G et al. An oncogene-Tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 16(3), 286-294 (2010
209. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem. Biophys. Res. Commun. 406(1), 70-73 (2011
210. Yu L, Todd NW, Xing L et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 127(12), 2870-2878 (2010
211. Shi L, Cheng Z, Zhang J et al. hsa-miR-181a and hsa-miR-181b function as tumor suppressors in human glioma cells. Brain Res. 1236, 185-193 (2008
212. Kono H, Nakamura M, Ohtsuka T et al. High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. Oncol. Rep. 30(1), 17-24 (2013
213. Srivastava A, Suy S, Collins SP, Kumar D. Circulating microRNA as biomarkers: An update in prostate cancer. Mol. Cell Pharmacol. 3(3), 115-124 (2011
214. Nolen BM, Lokshin AE. Biomarker testing for ovarian cancer: Clinical utility of multiplex assays. Mol. Diagn. Ther. 17(3), 139-146 (2013
215. Poruk KE, Gay DZ, Brown K et al. The clinical utility of CA 19-19 in pancreatic adenocarcinoma: Diagnostic and prognostic updates. Curr. Mol. Med. 13(3), 340-351 (2013
216. Bahrami A, Mortazavizadeh MR, Yazdi MF, Chamani M. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-13 assays in detecting symptomatic metastasis in breast cancer patients. East Mediterr. Health J. 18(10), 1055-1059 (2012
217. Redova M, Sana J, Slaby O. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol. 9(3), 387-402 (2013
218. Grasedieck S, Sorrentino A, Langer C et al. Circulating microRNAs in hematological diseases: Principles, challenges, and perspectives. Blood 121(25), 4977-4984 (2013
219. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 119(3), 586-593 (2010
220. Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q. Next-generation sequencing of microRNAs for breast cancer detection. J. Biomed. Biotechnol. 2011, 597145 (2011
221. Hu Z, Dong J, Wang LE et al. Serum microRNA profiling and breast cancer risk: The use of miR-484/191 as endogenous controls. Carcinogenesis 33(4), 828-834 (2012
222. Majid S, Dar AA, Saini S et al. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 72(24), 6435-6446 (2012
223. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S et al. Differential expression of miR-144. * as a novel fecal-based diagnostic marker for colorectal cancer. J. Gastroenterol. 46(12), 1391-1402 (2011
224. Mahn R, Heukamp LC, Rogenhofer S, Von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77(5), 1265 e1269-1216 (2011
225. Moltzahn F, Olshen AB, Baehner L et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 71(2), 550-560 (2011
226. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011
227. Ulivi P, Foschi G, Mengozzi M et al. Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. Int. J. Mol. Sci. 14(5), 10332-10342 (2013
228. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol. 23(8), 1157-1164 (2010
229. Xu J, Wu C, Che X et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 50(2), 136-142 (2011
230. Li LM, Hu ZB, Zhou ZX et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 70(23), 9798-9807 (2010
231. Zhou J, Yu L, Gao X et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol. 29(36), 4781-4788 (2011
232. Okada H, Kohanbash G, Lotze MT. MicroRNAs in immune regulation- opportunities for cancer immunotherapy. Int. J. Biochem. Cell Biol. 42(8), 1256-1261 (2010
233. Melo SA, Kalluri R. Molecular pathways: MicroRNAs as cancer therapeutics. Clin. Cancer Res. 18(16), 4234-4239 (2012
234. Kent OA, Chivukula RR, Mullendore M et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 24(24), 2754-2759 (2010
235. Kota J, Chivukula RR, O'donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6), 1005-1017 (2009
236. Kefas B, Floyd DH, Comeau L et al. A miR-297/hypoxia/DGK-Alpha axis regulating glioblastoma survival. Neuro Oncol. 15(12), 1652-1663 (2013
237. Martin A, Jones A, Bryar PJ et al. MicroRNAs-449a and-449b exhibit tumor suppressive effects in retinoblastoma. Biochem. Biophys. Res. Commun. 440(4), 599-603 (2013
238. Ma L, Reinhardt F, Pan E et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 28(4), 341-347 (2010
239. Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368(18), 1685-1694 (2013
240. Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting miR-21 for the Therapy of Pancreatic Cancer. Mol. Ther. 21(5), 986-994 (2013
241. Zhang Y, Roccaro AM, Rombaoa C et al. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 120(8), 1678-1686 (2012
242. Akao Y, Nakagawa Y, Hirata I et al. Role of anti-oncomirs miR-143 and-145 in human colorectal tumors. Cancer Gene Ther. 17(6), 398-408 (2010
243. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat. Rev. Drug Discov. 9(10), 775-789 (2010
244. Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438(7068), 685-689 (2005
245. Elmen J, Lindow M, Silahtaroglu A et al. Antagonism of microRNA-122 in mice by systemically administered LNA-AntimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36(4), 1153-1162 (2008
246. Elmen J, Lindow M, Schutz S et al. LNA-mediated microRNA silencing in non-human primates. Nature 452(7189), 896-899 (2008
247. Tomimaru Y, Eguchi H, Nagano H et al. MicroRNA-21 induces resistance to the anti-Tumour effect of interferon-Alpha/5-fluorouracil in hepatocellular carcinoma cells. Br. J. Cancer. 103(10), 1617-1626 (2010
248. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962), 198-201 (2010
249. Hutvagner G, Zamore PD. RNAi: Nature abhors a double-strand. Curr. Opin. Genetics Dev. 12(2), 225-232 (2002
250. Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol. Cell. Biol. 26(21), 8191-8201 (2006
251. Bader AG. miR-34-A microRNA replacement therapy is headed to the clinic. Front. Genet. 3, 120 (2012
252. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell. Biol. 18(10), 505-516 (2008
253. Trang P, Medina PP, Wiggins JF et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 29(11), 1580-1587 (2010
254. Moja L, Tagliabue L, Balduzzi S et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst. Rev. 4, CD006243 (2012
255. Gong C, Yao Y, Wang Y et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 286(21), 19127-19137 (2011
256. Nasser MW, Datta J, Nuovo G et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J. Biol. Chem. 283(48), 33394-33405 (2008
257. Cittelly DM, Das PM, Spoelstra NS et al. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer 9, 317 (2010
258. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31(12), 2049-2057 (2010
259. Hwang JH, Voortman J, Giovannetti E et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 5(5), e10630 (2010
260. Chen Y, Ke G, Han D, Liang S, Yang G, Wu X. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp. Cell Res. 320(1), 12-20 (2014
261. Cai J, Yang C, Yang Q et al. Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin. Oncogenesis 2, e75 (2013
262. Huang JY, Cui SY, Chen YT et al. MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS ONE 8(8), e72615 (2013
263. Huh JH, Kim TH, Kim K et al. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br. J. Cancer 109(2), 452-461 (2013
264. Chen PS, Su JL, Cha ST et al. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J. Clin. Invest. 121(9), 3442-3455 (2011
265. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-11 in cancer: Discovery, function and future perspectives. Cell Death Differ. 17(2), 215-220 (2010
266. Tang R, Li L, Zhu D et al. Mouse miRNA-709 directly regulates miRNA-15a/16-11 biogenesis at the posttranscriptional level in the nucleus: Evidence for a microRNA hierarchy system. Cell Res. 22(3), 504-515 (2012.